Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Abstract P204: Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer

Emily L. Chen, Nathan Hawkey, Beatrice C. Thomas, Kathryn E. Ware, Daniella Runyambo, Maureen Caligiuri, Erik Wilker, Erik J. Soderblom, M. Arthur Moseley, III, Sylvie M. Guichard, Andrew J. Armstrong, Jason A. Somarelli

Mol Cancer Ther (2021) 20 (12_Supplement): P204.

https://doi.org/10.1158/1535-7163.TARG-21-P204

Published: 01 December 2021

View articletitled, Abstract P204: Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer

Journal Articles

Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

Meghana M. Kulkarni, Jon Winter, David Whalley, ian Dale, Christopher Denz, Nin Guan, Deepa Bhavsar, Andrew Zhang, Timothy Rasmusson, Adrian Fretland, Sylvie M. Guichard

Mol Cancer Ther (2018) 17 (1_Supplement): A170.

https://doi.org/10.1158/1535-7163.TARG-17-A170

Published: 01 January 2018

View articletitled, Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

Journal Articles

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER⁺ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D'Cruz, James W.T. Yates, Michael Grondine, Zoe Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina C. Cosulich

Mol Cancer Ther (2015) 14 (11): 2508–2518.

https://doi.org/10.1158/1535-7163.MCT-15-0365

Published: 03 November 2015

View articletitled, AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Includes: Supplementary data

Journal Articles

Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma

Diana Cirstea, Loredana Santo, Teru Hideshima, Homare Eda, Yuko Mishima, Neeharika Nemani, Anuj Mahindra, Andrew Yee, Gullu Gorgun, Yiguo Hu, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M. Guichard, Kenneth C. Anderson, Noopur Raje

Mol Cancer Ther (2014) 13 (11): 2489–2500.

https://doi.org/10.1158/1535-7163.MCT-14-0147

Published: 03 November 2014

View articletitled, Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma

Includes: Supplementary data

Journal Articles

Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Nin Guan, Oona Delpuech, Danielle Greenawalt, Kelly Jacques, Farzin Gharahdaghi, Michael Zinda, Paul J. Smith, Sylvie M. Guichard

Mol Cancer Ther (2013) 12 (11_Supplement): C144.

https://doi.org/10.1158/1535-7163.TARG-13-C144

Published: 01 November 2013

View articletitled, Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Journal Articles

Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Stéphanie Arnould, Victoria J. Spanswick, Janet S. Macpherson, John A. Hartley, David E. Thurston, Duncan I. Jodrell, Sylvie M. Guichard

Mol Cancer Ther (2006) 5 (6): 1602–1609.

https://doi.org/10.1158/1535-7163.MCT-06-0018

Published: 03 July 2006

View articletitled, Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract P204: Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer

Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER⁺ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma

Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Email alerts

AACR Journals

Update search

Abstract P204: Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer

Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma

Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER⁺ Breast Cancer When Administered Using Intermittent or Continuous Schedules